Quote | PolyPid Ltd. (NASDAQ:PYPD)
Last: | $4 |
---|---|
Change Percent: | 0.25% |
Open: | $3.99 |
Close: | $4 |
High: | $4.11 |
Low: | $3.99 |
Volume: | 3,323 |
Last Trade Date Time: | 07/05/2024 03:00:00 am |
News | PolyPid Ltd. (NASDAQ:PYPD)
After a Reduction in Surgical Site Infection (SSI) Rates During COVID, Rates are Now Increasing, Signaling a Return to Pre-COVID Levels Known Procedure and Patient Risk-Factors Significantly Increase the Risk of SSIs and Impact Payer Costs Approximately 250 Patients of a Planned...
2023-05-10 07:25:24 ET PolyPid press release ( NASDAQ: PYPD ): Q1 GAAP EPS of $0.28 beats by $0.56 . As of March 31, 2023, the Company had cash and cash equivalents and deposits in the amount of $13.4 million, Research and development (R&D) expenses f...
Message Board Posts | PolyPid Ltd. (NASDAQ:PYPD)
Subject | By | Source | When |
---|---|---|---|
No posts yet. |
News, Short Squeeze, Breakout and More Instantly...
After a Reduction in Surgical Site Infection (SSI) Rates During COVID, Rates are Now Increasing, Signaling a Return to Pre-COVID Levels Known Procedure and Patient Risk-Factors Significantly Increase the Risk of SSIs and Impact Payer Costs Approximately 250 Patients of a Planned...
Submitted Revised Protocol for SHIELD II Phase 3 Trial to FDA to Evaluate D-PLEX 100 for Prevention of Abdominal Colorectal Surgical Site Infections ; Recruitment Expected to Re sume Imminently Received Advice from the Swedish Medical Prod...
PETACH TIKVA, Israel, April 26, 2023 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced that it will report its first quarter 2023 financial results...